3rd Bilateral Pathology Symposium

Richard Rosenquist Brandell was recently appointed Professor of Clinical Genetics at the Department of Molecular Medicine and Surgery, Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital, Sweden. He received his medical degree (1996) and PhD degree (1998) at Umeå University, Sweden, undertook a postdoctoral period at the Department of Pathology, Frankfurt am Main, Germany, and became specialist in Clinical Genetics 2004. Richard Rosenquist Brandell started his own research group at Uppsala University in 2000, focusing on molecular characterization of lymphoid malignancies, and his group rapidly became internationally renowned. He became Professor of Molecular Hematology in 2007 at the Department of Immunology, Genetics and Pathology, Uppsala University. He has initiated and led the SciLifeLab Clinical Genomics Facility in Uppsala between 2013-2017 and is currently Platform Director for the national Diagnostics Development Platform within SciLifeLab. More recently, he is coordinating the Genomics Medicine Sweden initiative that aims to build a new type of infrastructure within Swedish healthcare that implements precision medicine at a national level. By employing a translational approach and utilizing cutting-edge molecular tools, including next-generation sequencing technologies, Richard Rosenquist Brandell has made outstanding contributions to our understanding of the mechanisms behind the development of chronic lymphocytic leukemia (CLL), the most common adult leukemia. His studies have identified novel prognostic and predictive markers, defined new clinically relevant CLL subgroups, as well as provided significantly improved risk stratification at the individual patient level. Even more importantly, Rosenquist Brandell’s team has presented compelling evidence for a role of antigens (both autoantigens and microbial antigens) in the pathogenesis of CLL, which has generated great interest internationally. He has also built competitive networks at the national, European and international level. He is one of five founding members of an eminent European network of CLL researcher with an impressive combined cohort of more than 34, 000 CLL patients from 24 academic institutions.

Professor Csaba Bödör obtained his PhD degree from molecular oncology at Semmelweis University (Budapest, Hungary) in 2008, with special interest in molecular pathogenesis of hematological malignancies. He spent three years in Barts Cancer Institute (London, UK) with a postdoctoral research fellowship from the European Hematology Association (EHA). After his return to Hungary, he developed a research program on genomic and epigenetic background of B-cell lymphomas and familial myeloid malignancies in his home institution. He played a pivotal role in establishing the Hungarian Pediatric Oncology Molecular Profiling Program in Hungary and in introducing comprehensive genomic profiling into the daily routine algorithms in Hungary. He obtained certification clinical biochemistry, clinical laboratory genetics and molecular biology diagnostics. Currently, he is the head of the Molecular Pathology Division and the Molecular Oncohematology research group and deputy director at the Department of Pathology and Experimental Cancer Research, Semmelweis University in Budapest, Hungary.